StockData
Cardiff Oncology, Inc. logo

Cardiff Oncology, Inc. (CRDF) stock

CRDFNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$0.89+0.05 (+6.39%)

Close on Nov 19, 2026Market cap $69.44MP/E –Yield –

Cardiff Oncology enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Cardiff Oncology's enterprise value was $17.92M on Nov 11, 2026, against $92.38M a year earlier. Over the last 5 years it ranged from -$84.57M to $190.36M, with a median of $33.56M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$17.92M-86.0%
2025Dec 31, 2025$127.94M-16.8%
2024Dec 31, 2024$153.79M–
2023Dec 29, 2023-$15.28M–
2022Dec 30, 2022-$53.63M-151.7%
2021Dec 31, 2021$103.71M-76.2%
2020Dec 31, 2020$436.48M–
2019Dec 31, 2019-$1.05M–
2018Dec 31, 2018-$2.90M-150.2%
2017Dec 29, 2017$5.77M-86.3%
2016Dec 30, 2016$42.20M-58.5%
2015Dec 31, 2015$101.62M+56.7%
2014Dec 31, 2014$64.85M-20.1%
2013Dec 31, 2013$81.16M-10.3%
2012Dec 31, 2012$90.46M–

More Cardiff Oncology figures

See a number that looks wrong?